448 related articles for article (PubMed ID: 19018868)
1. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Dasanu CA; Alexandrescu DT
Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
[TBL] [Abstract][Full Text] [Related]
2. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Boruah PK; Bolesta S; Shetty SM
Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
4. Neutrophilic dermatosis complicating lenalidomide therapy.
Thieu KP; Rosenbach M; Xu X; Kist JM
J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
[TBL] [Abstract][Full Text] [Related]
5. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Sher T; Miller KC; Lee K; Chanan-Khan A
Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide-induced interstitial lung disease.
Chen Y; Kiatsimkul P; Nugent K; Raj R
Pharmacotherapy; 2010 Mar; 30(3):325. PubMed ID: 20180616
[TBL] [Abstract][Full Text] [Related]
8. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
10. A case of lenalidomide-induced hypersensitivity pneumonitis.
Lerch E; Györik S; Feilchenfeldt J; Mazzucchelli L; Quadri F
Onkologie; 2010; 33(5):249-52. PubMed ID: 20502059
[TBL] [Abstract][Full Text] [Related]
11. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Srinivasan S; Schiffer CA
Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2007 Aug; 11(4):569-74. PubMed ID: 17723971
[TBL] [Abstract][Full Text] [Related]
14. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
[No Abstract] [Full Text] [Related]
15. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
16. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
18. Concurrent radiation therapy and lenalidomide in myeloma patient.
Marchand V; Decaudin D; Servois V; Kirova YM
Radiother Oncol; 2008 Apr; 87(1):152-3. PubMed ID: 18077032
[No Abstract] [Full Text] [Related]
19. Reversible pulmonary toxicity due to lenalidomide.
Coates S; Barker A; Spurgeon S
J Oncol Pharm Pract; 2012 Jun; 18(2):284-6. PubMed ID: 21742815
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Niesvizky R; Naib T; Christos PJ; Jayabalan D; Furst JR; Jalbrzikowski J; Zafar F; Mark T; Lent R; Pearse RN; Ely S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M
Br J Haematol; 2007 Sep; 138(5):640-3. PubMed ID: 17686058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]